In the phase II ATLANTIC study, the investigators assessed the effect of durvalumab (anti-PD-L1) treatment as third-line or later treatment in three cohorts of patients with NSCLC defined by EGFR/ALK status and tumor expression of PD-L1. Here, EGFR is linked to non-small cell lung carcinoma.